IO BIOTECH INC. - COM

0,7480

26-ноября-24 15:45:00

15 мин. задержка

Акции

-0,0020

-0,27%

Сегодняшний диапазон

0,7100 - 0,7850

ISIN

N/A

Источник

NASDAQ

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

12 ноя 2024 06:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Participation in Upcoming Investor Conferences

11 ноя 2024 15:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

07 ноя 2024 09:00:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

14 сен 2024 01:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

30 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Participation in Upcoming Investor Conferences

26 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

13 авг 2024 06:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

25 июл 2024 15:05:00 Источник Nasdaq GlobeNewswire
IO Biotech to Present at Jefferies Global Healthcare Conference

23 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

14 май 2024 06:55:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 15:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

15 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

09 апр 2024 11:00:00 Источник Nasdaq GlobeNewswire
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

05 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

06 мар 2024 15:11:01 Источник Nasdaq GlobeNewswire
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

05 мар 2024 15:40:01 Источник Nasdaq GlobeNewswire
IO Biotech to Present at 44th Annual Cowen Health Care Conference

26 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

21 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces 2023 Third Quarter Results

13 ноя 2023 07:12:16 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.